Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical

Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical is a high-tech pharmaceutical company specializing in the research, development, production, and sale of peptide drugs and their amino acid derivatives. Established in 2000, the company operates advanced GMP-compliant manufacturing facilities for peptide active pharmaceutical ingredients (APIs) and finished dosage forms, including small-volume injections and lyophilized powder injections. Tianji Biopharmaceutical provides comprehensive peptide CRO/CDMO services, covering process research, purification, formulation development, and commercial production. In addition to its robust portfolio of generic peptide APIs and finished products like semaglutide, liraglutide, and thymalfasin, the company is transitioning toward an innovation-driven model, highlighted by its proprietary Class 1 innovative peptide-drug conjugate (PDC) program, BGC0222, which is currently in Phase 1 clinical development for advanced solid tumors.